Company intelligence / Profile preview
CSPC Ouyi Pharmaceutical
- Ownership
- Private
- Development stage
- Commercial
Overview
CSPC Ouyi Pharmaceutical is a major subsidiary of CSPC Pharmaceutical Group focused on the development and internationalization of new pharmaceutical products. It has multiple approved drugs in China across small molecules and nano-formulations. Recent clinical milestones include FDA approvals for clinical trials in oncology and cardiovascular indications as well as NMPA approval for a nano-formulation breast cancer therapy[10]. The company leverages advanced platforms in siRNA therapeutics and ADCs[6].
- Therapeutic areas
- CardiovascularImmunologyEndocrinologyOncologyNeurology
- Modalities
- Small moleculeLiposomal drugNano-formulation drugMonoclonal antibody (via parent group)Antibody-drug conjugate (via parent group)
- Industry
- Biotech
Drug pipeline
13 assets12 more assets in the full pipeline.
Partnerships
Beyond the preview
Go deeper on CSPC Ouyi Pharmaceutical.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CSPC Ouyi Pharmaceutical.